Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of M207 Formulations vs Zolmitriptan Nasal Spray
NCT03978403Phase 1Completed
- Sponsor
- Zosano Pharma
- Start
- May 2019
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ZP-Triptan in migraine (4 arms), sponsored by Zosano Pharma. Primary endpoints: Maximum Plasma Concentration at 24 hours, Time to Maximum Plasma Concentration at 24 hours and 1 more. Started May 2019; status: completed.
02
Drugs
ZP-Triptan
03
Conditions
migraine
Beyond the preview
Go deeper on NCT03978403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03978403.